What is the activity of fosfomycin against Pseudomonas aeruginosa and what dosing and combination therapy are recommended?

Fosfomycin Coverage for Pseudomonas aeruginosa

Fosfomycin has limited intrinsic activity against Pseudomonas aeruginosa and should NOT be used as monotherapy; when used, it must be combined with other active antipseudomonal agents, with susceptibility testing mandatory before treatment initiation.

Activity Against Pseudomonas

Fosfomycin demonstrates poor standalone activity against P. aeruginosa:

• Susceptibility rates are low: Only 7.1-27.1% of isolates are inhibited at clinically achievable concentrations 1
• The FDA label does not list P. aeruginosa among organisms for which clinical efficacy has been established 2
• Resistance emerges rapidly during monotherapy, often within 24-48 hours 3, 4

When to Consider Fosfomycin for Pseudomonas

Indication Criteria

Use fosfomycin only in the following scenario:

• Severe carbapenem-resistant P. aeruginosa (CRPA) infections where the isolate is susceptible to fosfomycin AND limited treatment options exist (polymyxins, aminoglycosides, or fosfomycin only) 5

Critical Prerequisites

1. Mandatory susceptibility testing must confirm fosfomycin activity 6
2. Synergy testing should be performed when possible to guide combination selection 6
3. Never use as monotherapy - resistance amplification occurs within 24-48 hours 3, 4

Combination Therapy Recommendations

For severe CRPA infections, use fosfomycin with at least one other in vitro active drug 5. The evidence supports these specific combinations:

Preferred Combinations (Based on Evidence Quality)

1. Fosfomycin + Polymyxins (Colistin)

• Demonstrated synergy in 7/10 isolates in time-kill studies 1
• Highest biofilm inhibition rates when combined 7
• Used successfully in ICU patients with 54.2% treatment efficacy 6

2. Fosfomycin + Aminoglycosides (Amikacin or Gentamicin)

• Amikacin-fosfomycin combination achieved 6-log kill within 24 hours 4
• Effectively suppressed resistance emergence 4
• Gentamicin showed 19.1% synergy rate 8

3. Fosfomycin + Beta-lactams

• Ceftazidime-avibactam + fosfomycin: Superior to monotherapy in murine models (2-5 log reduction vs. controls) 9
• Ceftazidime alone showed 23.4% synergy rate 8
• Cefepime demonstrated high biofilm inhibition 7

Dosing Strategy

Optimize fosfomycin administration for Pseudomonas:

• Intravenous route only (oral formulation achieves inadequate systemic levels) 2
• High-dose regimens: 18-24 g/day divided doses 3
• Continuous or prolonged infusion preferred over intermittent dosing to maximize time above MIC, which is linked to resistance suppression 3
• Short dosing intervals (every 8 hours) if continuous infusion unavailable 3

Critical Contraindications and Precautions

Avoid fosfomycin in patients with:

• Hypernatremia
• Cardiac insufficiency
• Renal insufficiency 6

Monitor for:

• Reversible severe hypokalemia (occurred in 6.3% of ICU patients) 6
• Rapid resistance emergence if inadequate dosing or monotherapy used

Clinical Reality Check

The translational gap is substantial: While in vitro and animal studies show promise, clinical data for fosfomycin against Pseudomonas remains limited to observational studies with modest efficacy (54.2% treatment success, 37.5% 28-day mortality in ICU patients) 6. The 2022 ESCMID guidelines explicitly state there is insufficient evidence for newer agents like ceftolozane-tazobactam, imipenem-relebactam, and ceftazidime-avibactam against CRPA, and fosfomycin falls into an even lower evidence tier 5.

Practical Algorithm

1. Confirm CRPA with limited options (resistant to carbapenems, cephalosporins, fluoroquinolones)
2. Perform susceptibility testing for fosfomycin and all available agents
3. If fosfomycin susceptible AND ≥1 other active agent available: Consider combination therapy
4. Select combination partner based on susceptibility: polymyxin > aminoglycoside > beta-lactam
5. Dose aggressively: IV fosfomycin 18-24 g/day by continuous infusion + partner drug
6. Monitor closely: Electrolytes (especially potassium), clinical response at 48-72 hours
7. If clinical failure or resistance emerges: Switch to alternative regimen immediately

Bottom line: Fosfomycin is a salvage option for CRPA, not a first-line agent, and its use demands combination therapy with aggressive dosing strategies.